EOLS News and Press, Evolus Inc. From 02/02/22

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that members of its management team will be participating in the Virtual 11th Annual SVB Leerink Global Healthcare Conference. An a...

• Q4 2021 Preliminary Unaudited Net Revenue of Approximately $34.7 Million, Up 68% from Q4 2020 • Full-Year 2021 Preliminary Unaudited Net Revenue of Approximately $99.7 Million, Up 76% Over 2020 • 2022 Net Revenue Expected to be $143 to $150 Million Represe...

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that it has further strengthened and diversified its Board of Directors with the appointment of digital and beauty innovator Brady Stew...

Company Anticipates Strong Finish to 2021 Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that its common stock has been selected for inclusion in the Nasdaq Biotechnology...

Evolus (EOLS +1.9%) has announced that it has entered into a $125M term loan financing facility in two tranches with funds managed by Pharmakon Advisors. Under the terms, the proceeds will be used for general corporate purposes and working capital and may also be used for potential ...

Initial Draw of $75 Million Expected to Fund Company Beyond Cash Flow Breakeven Second Draw of $50 Million Provides Financial Flexibility for Potential Strategic Transactions Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach f...

Gainers: Arhaus (NASDAQ:ARHS) +6%. Radware (NASDAQ:RDWR) +5%. Liquidity Services (NASDAQ:LQDT) +5%. Digital World Acquisition (NASDAQ:DWAC) +3%. Big 5 Sporting Goods (NASDAQ:BGFV) +26%. Losers: Lucid Group (NASDAQ:LCID) -8%. Relmada Therapeutics (NASDAQ:RLMD) -7%. VectivBio Holding AG (NASDAQ...

NEWPORT BEACH, Calif., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that members of its management team will be participating in two investment confer...

Evolus, Inc. (EOLS) Q3 2021 Earnings Conference Call November 2, 2021 09:00 a.m. ET Company Representatives David Moatazedi - President, Chief Executive Officer Lauren Silvernail - Chief Financial Officer, Executive Vice President, Corporate Development Rui Avelar - Chief Medical Officer, Hea...

Evolus (NASDAQ:EOLS) began a clinical program to study an “extra strength” dose for extended duration of Jeuveau (prabotulinumtoxinA-xvfs) its flagship neurotoxin product for aesthetics. Our proven clinical development team has initiated Phase II study preparation, and we l...